Decentralized trials shift more of the study’s activity away from a small number of investigative sites and toward participants, local providers, and remote monitoring. Most of the attention that shift gets is technical: what tools support remote data collection, how a site connects to a central system, what security a distributed setup needs. Less attention goes to a question that matters just as much to a CRO running the study: when the trial’s activity is spread across more locations, what happens to the committees and processes responsible for overseeing it?
Decentralization Multiplies Places, Not Just Data Points
A traditional, site-based trial concentrates activity in a handful of locations, which makes coordinating oversight relatively straightforward: a defined set of sites, a defined set of relationships, a manageable number of places a decision has to reach. A decentralized trial multiplies that. More locations are generating information, more local providers are involved, and the oversight process has to reach and account for all of them consistently, not just the smaller set of central sites a traditional design would have relied on.
That is a coordination problem before it is a technology problem. A CRO can equip every location with capable tools for its own piece of the work and still lack a single, consistent process for how oversight committees review that work, approve changes, and confirm that every location received them the same way and on the same timeline.
It is worth being precise about what does and does not change with decentralization. The clinical and regulatory expectations placed on the trial do not relax because the work is spread across more locations; if anything, more locations mean more places where a protocol has to be followed correctly and more places a deviation could originate. What changes is the operational surface area the oversight process has to cover, and a process built for a handful of sites will not automatically scale to cover many more just because the underlying expectations stayed the same.
Where the Readiness Gap Actually Shows Up
The gap rarely shows up as a single failure. It shows up as small inconsistencies that are easy to miss until someone is asked to account for them: one location working from an outdated version of a procedure, a committee decision that reached most but not all of the relevant sites, a status update that took real effort to assemble because no single view of the distributed trial existed. None of those inconsistencies are dramatic on their own. Across a trial running in dozens of locations instead of a handful of sites, they accumulate quickly.
Readiness, in that sense, is not primarily about whether each individual location has adequate technology. It is about whether the CRO has one governed process that reaches every location the same way, regardless of how many there are or how far apart they operate.
It is also easy to overestimate readiness by looking at the wrong evidence. A pilot involving a handful of decentralized sites can look completely under control, because a small number of locations is still within the range an informal process can manage through extra effort. That success is not necessarily evidence the same process will hold at a larger scale; it may simply mean the informal approach has not yet been asked to cover enough locations to show its limits.
Standardizing Across a Distributed Footprint
Meeting that requires treating oversight the same way for a decentralized trial as it would be treated for a traditional one, standardized and centrally governed, rather than assuming decentralization has to mean decentralized process as well:
- Control: the same review and approval sequence applies regardless of which location a piece of work originated from, so the trial’s process does not fragment along with its footprint.
- Oversight: committee leadership can see the status of work across every location at once, instead of assembling that picture from separate updates by site.
- Capacity: the work of reconciling status across many dispersed locations goes to the process itself, not to whoever on the study team happens to be tracking it that week.
- Inspection-Readiness: the record of what was reviewed, approved, and communicated to which location exists as a byproduct of the process, available on demand rather than reconstructed from records held in as many places as the trial itself runs.
Readiness Is a Governance Question First
A CRO evaluating its readiness for decentralized trials is often, without naming it that way, evaluating whether its governance can scale past a handful of familiar sites. That question sits alongside, not underneath, the technology questions a decentralized trial raises about data collection and remote monitoring. A governed execution environment gives a CRO a consistent way to run oversight across however many locations a given trial touches, which is what lets decentralization expand a trial’s reach without the process behind it becoming the thing that cannot keep up. Sponsors and CROs weighing a more decentralized design are best served by asking that governance question before the trial’s footprint is already larger than the process was built for.
The trials most likely to expand into a decentralized design are, almost by definition, the ones with the most locations for a process to reach consistently. Asking whether the governance can scale before committing to the design, rather than discovering the answer partway through the trial, is the difference between decentralization that extends a CRO’s reach and decentralization that outgrows the process meant to hold it together.